Free Trial
OTCMKTS:CXRXF

ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis

ADVANZ PHARMA logo
$17.06 0.00 (0.00%)
As of 06/10/2021

About ADVANZ PHARMA Stock (OTCMKTS:CXRXF)

Key Stats

Today's Range
$17.06
$17.06
50-Day Range
$17.06
$17.06
52-Week Range
$2.13
$18.00
Volume
39 shs
Average Volume
11,851 shs
Market Capitalization
$834.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive CXRXF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter.

CXRXF Stock News Headlines

PHAT Phathom Pharmaceuticals, Inc.
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

CXRXF Stock Analysis - Frequently Asked Questions

ADVANZ PHARMA's stock was trading at $17.06 on January 1st, 2025. Since then, CXRXF stock has increased by 0.0% and is now trading at $17.06.

Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
OTCMKTS:CXRXF
CIK
N/A
Fax
N/A
Employees
429
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$74.86 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$525.58 million
Price / Cash Flow
N/A
Book Value
$0.16 per share
Price / Book
106.63

Miscellaneous

Free Float
N/A
Market Cap
$834.46 million
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (OTCMKTS:CXRXF) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners